Novavax has a readout on its COVID-19 vaccine Phase 1/2 data on Friday, October 30, 2020 at the CDC Advisory Committee on Immunization Practices (ACIP) meeting. During the meeting, they will also release Phase 2 reactogenicity data.
They are planning to begin the Phase 3 trial for their COVID-19 vaccine in November 2020 in the U.S. They also have a Phase 3 trial planned in the U.K. which they are expecting interim data as soon as Q1 2021.
Read more here.